Concepedia

Haris Jahić

HJ

12

Publications

1.3K

Citations

12

H-Index

2004

Active since

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (Brazil)

Haris Jahić is an author at AstraZeneca (United States) specializing in medicine, pharmacology, and biochemistry.

ORCID

Top concepts

Publications per year

2004–2024

12

Publications

12

Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor

David E. Ehmann, Haris Jahić, Philip L. Ross et al. · Proceedings of the National Academy of Sciences · 2012 · 507 citations · Full text

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

David E. Ehmann, Haris Jahić, Philip L. Ross et al. · Journal of Biological Chemistry · 2013 · 348 citations · Full text

, , +16

Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48

Sushmita D. Lahiri, Stefano Mangani, Haris Jahić et al. · ACS Chemical Biology · 2014 · 99 citations

, , +22

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

Adam B. Shapiro, Ning Gao, Haris Jahić et al. · ACS Infectious Diseases · 2017 · 58 citations

, , +21

Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers

Kevin M. Cottrell, Kimberly J. Briggs, Douglas A. Whittington et al. · Journal of Medicinal Chemistry · 2024 · 58 citations · Full text

Rows per page

1–5 of 12